These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21658751)

  • 1. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
    Fauci JM; Whitworth JM; Schneider KE; Subramaniam A; Zhang B; Frederick PJ; Kilgore LC; Straughn JM
    Gynecol Oncol; 2011 Sep; 122(3):532-5. PubMed ID: 21658751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
    Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
    Hanna RK; Poniewierski MS; Laskey RA; Lopez MA; Shafer A; Van Le L; Crawford J; Dale DC; Gehrig PA; Secord AA; Havrilesky LJ; Lyman GH
    Gynecol Oncol; 2013 Apr; 129(1):74-80. PubMed ID: 23262376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
    Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
    JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
    Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
    Landrum LM; Java J; Mathews CA; Lanneau GS; Copeland LJ; Armstrong DK; Walker JL
    Gynecol Oncol; 2013 Jul; 130(1):12-8. PubMed ID: 23578540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.
    Nagel CI; Backes FJ; Hade EM; Cohn DE; Eisenhauer EL; O'Malley DM; Fowler JM; Copeland LJ; Salani R
    Gynecol Oncol; 2012 Feb; 124(2):221-4. PubMed ID: 22055764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
    Sorbe B; Graflund M; Nygren L; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Oncol; 2012 Mar; 40(3):773-81. PubMed ID: 22159569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
    Ebata T; Yunokawa M; Yoshida H; Bun S; Shimoi T; Shimomura A; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
    Int J Gynecol Cancer; 2017 Nov; 27(9):1850-1855. PubMed ID: 29040183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
    García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
    Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
    Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ
    Acta Oncol; 2016; 55(2):226-33. PubMed ID: 26079434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
    Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
    Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
    Sivakumaran T; Mileshkin L; Grant P; Na L; DeFazio A; Friedlander M; Obermair A; Webb PM; Au-Yeung G;
    Gynecol Oncol; 2020 Jul; 158(1):47-53. PubMed ID: 32381362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
    Glaze S; Teitelbaum L; Chu P; Ghatage P; Nation J; Nelson G
    J Obstet Gynaecol Can; 2013 Jan; 35(1):61-7. PubMed ID: 23343799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.